{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-258568","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.407580+00:00","generated_at":"2026-05-30T00:23:47.921921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data","bullets":["Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.","Cash and equivalents at $17.7M as of Sept 30, 2024, expected to fund operations into June 2025.","Phase 1b high-dose LTI-03 (5mg BID) in IPF showed dose-dependent biomarker effects; combined cohort data achieved statistical significance in 4 of 8 biomarkers.","Planning underway for Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF).","Exclusive option agreement with Advancium Health Network for ALRN-6924 (oncology) granted; non-refundable fee received, potential milestone and royalty payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-258568","json":"https://secwatch.observer/filing/0001193125-24-258568.json","markdown":"https://secwatch.observer/filing/0001193125-24-258568.md","text":"https://secwatch.observer/filing/0001193125-24-258568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524258568/0001193125-24-258568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524258568/d912402d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:23:47.921921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}